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INTRODUCTION 
 
The oligodendrocyte is a crucial structural and functional element of the 
central nervous system (CNS). A variety of disorders affect these cells, which 
may lead to their loss, resulting in neurological deficits, suffering, and death. 
Clinical therapies are lacking in virtually all of these diseases. Stem cell 
technologies and cell transplantation offer a potential avenue of treatment for the 
broad spectrum of oligodendrocyte pathologies.  
 
Oligodendrocytes & Oligodendrocyte Pathology 
 
The major role of oligodendrocytes is the production of lipid rich myelin 
sheaths that segmentally envelop axons, serving as insulation, and organizing 
distribution of voltage gated channels. They so enable saltatory conduction of 
signals throughout the neuraxis [1]. In addition, the oligodendrocyte provides 
protection and trophic factors of vital importance to the survival of axons, such as 
proteolipid protein (PLP) and sirtuin 2 [2-5]. Without these provisions, the CNS is 
not able to operate properly.  
Dysmyelination results in loss of organization of voltage-dependent 
channels on the axolemma [4, 5]. Initially, this causes conduction block, but 
subsequently, by a compensatory mechanism, voltage gated sodium channels 
NaV 1.2, are inserted into the previously internodal axonal membrane [1].  These  
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channels, which are ordinarily expressed on neurons only prior to myelination, 
enable propagation of action potentials due to their small sodium conductance [6, 
7]. However, NaV 1.6 channels, normally expressed only at the nodes of Ranvier 
following myelination, also become widely distributed across the axolemma [8]. 
Their high sodium conductance leads to a pathological increase in the 
cytoplasmic concentration of sodium, causing protease activation and axonal 
degeneration.  
Myelin can also play a protective role as it shields the axon from 
inflammatory mediators. During an inflammatory process, such mediators are 
released into the axonal environment, where in absence of myelin they deplete 
ATP and disturb mitochondrial function, resulting in malfunction of oxidative 
metabolism within the axon itself. The Na+-K+ ATPase that is required for 
extruding sodium from the axon fails, leading to high sodium concentrations [9]. 
This in turn increases the activity of the Na+-Ca2+ exchange channel, which 
requires influx of more calcium ions, to counter the efflux of sodium [10]. High 
intra-axonal calcium concentrations in turn activate axonal proteases, which lead 
to fragmentation of neurofilament, thus disintegrating axonal structure and 
disturbing axonal transport [11].  
Several oligodendrocyte factors have been identified that appear to have a 
primary role of maintaining axonal stability, rather than being responsible for 
myelin formation. Transgenic mice lacking proteolipid protein (Plp) for example, 
an integral myelin sheath protein, show long term axonal degeneration in spite of  
2 
normal myelin formation [3]. Similar conclusions can be made from observations 
in human demyelinating conditions, such as multiple sclerosis (MS), where 
remyelination prevents axonal degeneration [12], or Pelizaeus-Merzbacher 
disease where lack of myelin leads to axonal loss [2].  
 
Disorders affecting oligodendrocytes are numerous and invariably result in 
profound morbidity, many ultimately leading to death. They can be divided into 
two main categories: primary and secondary – based on the relationship between 
oligodendrocytes and the initial locus of pathology [13]. Primary demyelination 
results either from inborn errors of metabolism within, or direct inflammatory 
damage to oligodendrocytes. Genetic disorders affecting myelination can be 
grouped into those affecting lysosomal function (metachromatic leukodystrophy 
and Krabbe’s disease), those impairing peroxisomal function, such as 
adrenoleukodystrophy, and those resulting in deficient or abnormal myelin 
proteins (Pelizaeus-Merzbacher disease) [14]. Although relatively rare, with onset 
in early infancy, these disorders are a cause of great suffering and early death.  
MS is the prototypical inflammatory disorder leading to loss of myelin, and the 
most common inflammatory disorder of the CNS. With a lifetime risk of 1 in 400 
and onset in young adulthood, this disabling disease represents a significant 
burden on the population of the northern latitudes [15]. The cost of the disease is 
estimated to be $ 47,215 per patient per year in the United States [16], and in the 
European Union alone, the yearly cost of this disease is estimated to total 9  
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billion euros [17]. While our understanding of the underlying pathophysiology 
is very limited, it ultimately results in loss of oligodendrocytes and subsequent 
degeneration of axons, the cause of permanent neurological sequelae [13].  
Secondary demyelination occurs after non-selective insults to all elements of 
the CNS, where oligodendrocytes are bystanders in the way of generalized 
pathology – such as ischemia, infection, or trauma.  
A significant subset of patients with cerebral palsy includes those with 
periventricular leukomalacia. This disorder is characterized by loss of 
oligodendroglia and/or their precursors in the later stages of fetal development, 
due to a variety of possible insults in utero [13]. Absence of myelinated white 
matter is the direct cause of debilitating features of this disorder.  
Progressive multifocal leukoencephalopathy (PML) is an infectious disorder, 
related to immune suppression and is seen almost exclusively in patients with 
HIV/AIDS. It is related to reactivation of the polyomavirus JC which induces a 
lytic infection of oligodendrocytes. The disease is fatal in most cases, but 
survivors are left with permanent neurological deficits due to the subcortical 
demyelinating process [18]. Another etiology of myelin loss is acute 
demyelinating encephalomyelitis. This rare and poorly understood process 
involves an immune attack directed against oligodendrocytes, in the wake of a 
generalized viral or bacterial infection. It has been associated with measles, 
varicella, infectious mononucleosis, and non-specific febrile illness. Although 
most patients recover completely, some are left with permanent disability due to  
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loss of myelin [19].  
Stroke, one of the most common causes of neurological disability, is caused 
by non-discriminatory loss of CNS tissue due to ischemia. Among all cell types 
that make up the CNS are oligodendrocytes and their precursors, which are lost 
after their nutrient supply is cut off. Specifically, stroke can occur in areas of 
white matter, thus leading to demyelinating lesions.  
Traumatic injury to the CNS, especially of spinal cord, leads to loss of tissue 
due to direct mechanical disruption. The initial area of injury however is 
broadened, regardless of location in the CNS axis, by secondary injury 
mechanisms. Disruption of vasculature and the blood-brain-barrier leads to 
infiltration of elements – molecules and cells of the immune system – that are 
harmful to the neighboring non-injured tissue. Extravasation of blood into the 
nervous tissue triggers activation of the clotting cascade needed for coagulation. 
Subsequent activation of complement and release of cytokines by a variety of the 
components of injured tissue cause an influx of leukocytes and macrophages, 
further augmenting the inflammatory reaction. All these processes lead to 
generation of free radicals and reactive oxygen species that cause more damage 
in the previously intact region bordering the epicenter of injury. Furthermore, 
prohibitive to regeneration are myelin debris itself and formation of an astrocytic 
scar [20, 21]. Excitotoxicity and direct cellular damage lead to apoptosis of both 
neurons and oligodendrocytes. Loss of oligodendrocytes and myelin around 
intact axons exposes them to injury, dysfunction and disintegration, as described 
5 
above. Indeed, it is this loss of myelin that contributes to deterioration of 
neurological function following initial spinal cord injury [22].  
Evidence is starting to emerge implicating oligodendrocyte pathology in 
certain neurodegenerative and psychiatric disorders, such as ALS [23], 
schizophrenia and bipolar disorder [24, 25]. The relationship of the diseased 
oligodendrocytes in those conditions however is not yet known.  
 
Endogenous Remyelination  - The Oligodendrocyte Progenitor Cell 
 
 The adult CNS retains the ability to regenerate oligodendrocytes that are 
lost due to a variety of pathological mechanisms. Such regenerated 
oligodendrocytes are able to functionally remyelinate the denuded axons left in 
the wake of the insult. The process of remyelination occurs in a variety of 
experimental settings in adult animals, such as the cuprizone induced 
demyelination model [26], after direct delivery of lysolecithin or ethidium bromide 
[27], and in experimental autoimmune encephalomyelitis [13]. Evidence for 
remyelination exists also in cases of traumatic injury, specifically after spinal cord 
injury [28], where myelin can arise from Schwann cells of peripheral nerve and 
central progenitor cell origin [29]. In the adult human, remyelination is commonly 
seen in cases of MS [30]. 
 The degree to which surviving mature oligodendrocytes can contribute to 
remyelination is not completely resolved, but existing evidence indicates that this  
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is little or none. Instead, oligodendrocyte proliferation and remyelination are 
linked to the adult oligodendrocyte progenitor cell (OPC), a pluripotent glial 
precursor found in the CNS [13]. OPCs are found in both white and gray matter, 
representing approximately 5-8% of the cell population (similar to the density of 
microglia) [31]. They are multi-processed cells, characterized by the expression 
of markers such as the proteoglycan NG2, the platelet-derived growth factor 
receptor-α (PDGFR-α), the bHLH transcription factors Olig1 and Olig2, and O4 
(13, 31 – 33). The evidence suggesting OPCs as the primary mediators of 
remyelination is indirect, but multifaceted, and based mainly on rodent studies 
[13, 32]. Indirect retroviral and autoradiographic tracing has demonstrated that 
cells dividing within the white matter can give rise to remyelinating 
oligodendrocytes [33, 34]. Focal areas of demyelination tend to harbor OPCs 
before the appearance of oligodendrocytes, with a spatial and temporal pattern 
supporting the idea that OPCs repopulate damaged white matter and lead to 
remyelination [31, 35]. Finally, OPCs that are transplanted into demyelinated 
areas restore the lost myelin with great efficiency [13].  
 In response to injury, astrocytes and microglia secrete a variety of signals 
likely to activate the endogenous OPC population [36-38]. OPCs undergo a 
transition from a quiescent state to proliferation, changing morphology [31] and 
upregulating expression of genes that are associated with their development. In 
fact, many parallels can be drawn between the normal developmental process of 
myelination and remyelination following oligodendrocyte pathology. The guiding 
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cellular mechanisms in both instances involve the same molecular players and 
are summarized in Figure 1 [36].  
 
Figure 1. Putative remyelination mechanisms, adapted from Patel and Klein ,2011 [36]. Depicted 
are roles for cytokines, chemokines, growth factors, transcription factors and other signaling 
proteins in remyelination of demyelinated lesions in MS. During demyelination, oligodendrocytes 
undergo apopotosis, leaving debris, which may contribute to the activation of microglia and 
astrocytes, which then express cytokines (TNF-a, IL-1b). Cytokines alter expression of 
chemokines (CXCL1, CXCL2, CXCL12) and growth factors (IGF-1, PDGF, FGF,EGF), whose 
activation or inhibition of various aspects of remyelination are depicted via color-coding of arrows 
and signs of blockade, respectively, for each biologic process (migration, proliferation, OPC 
survival and differentiation). For certain molecules, such as CXCL1/2, opposing effects on OPCs 
have been observed, depending on the animal model used. Growth factors differentially impact 
on cell survival and proliferation while chemokines contribute to migration and differentiation, 
depending on OPC position.TLR2 activation inhibits OPC differentiation. Notch-1 also blocks 
OPC differentiation to promote migration. Molecules that regulate OPC maturation are depicted in 
the context of intracellular signaling during differentiation. Included are chemokine (CXCR4/7, 
CXCR2) and growth factor (IGF-1R, EGFR) receptors, miRNAs, Lingo-1 and several transcription 
factors (Nkx2.2, Olig1/2, Mash1, Tcf4, SOX10) which may negatively or positively impact on the 
expression of myelin proteins including proteolipid protein (PLP), myelin basic protein (MBP) and 
myelin oligodendrocyte glycoprotein (MOG). 
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Development of the Oligodendrocyte Progenitor Cell 
 
 OPCs arise in the ventral aspect of the neural tube, during the middle 
period of neurogenesis. Sonic hedgehog (SHH) signaling is of crucial importance 
for the induction of this progenitor population. From their ventral origin they 
migrate dorsally, causing a ventral to dorsal myelination gradient. This temporal 
and spatial relationship of the initial OPC wave is seen throughout the entire 
neuraxis, in humans as well in rodents. In the telencephalon, the initial OPC 
spread originates from the medial and lateral ganglionic eminences, emerging in 
the rostral migratory pathway. Later on however, OPCs are generated in the 
dorsal cortical subventricular zone (SVZ). There is further evidence suggesting 
multiple origins of OPCs throughout the developing CNS, especially during 
human fetal development [32, 39]. 
OPCs from the SVZ are characterized by their expression of glial fibrillary acidic 
protein (GFAP), and give rise to both oligodendrocytes and astrocytes, and are 
capable of self-renewal. OPCs residing in the hippocampus however, are also 
able to generate neurons [13]. The different origins of OPCs may suggest 
redundancy, or that they differ in other aspects as well, such as the type of axon 
or pathway they go on to myelinate. The common thread however is their 
widespread migration and differentiation into myelinating oligodendrocytes. 
Furthermore, if one of the OPC origins is destroyed, the others are capable of 
taking over, ultimately resulting in intact myelination of the entire CNS [40].  
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Failure of Endogenous Remyelination and Rationale for Exogenous 
Therapy 
 
 In spite of ample evidence that remyelination is possible after a variety of 
insults to the white matter, it is insufficient in most instances, thus failing to 
rescue the affected organism from neurological deficit. MS and traumatic injury 
are prime examples of this scenario, among others mentioned above. This fact 
lays down the foundation for a rationale for exogenous oligodendrocyte 
replacement and remyelination therapies.  
 Endogenous OPCs fail to remyelinate for a number of reasons. Age has 
been shown to correlate inversely with the efficiency of remyelination, as it 
decreases the efficiency of OPC recruitment and their ability to differentiate [41-
43]. Histone deacetylases, which play an important role in OPC differentiation, 
are impaired in older animals [44, 45]. A disparity has also been observed 
between the different sexes, with decline in remyelination capability occurring 
faster in male than female rats [46]. The aging of the host environment could also 
be responsible for the observed trend. Macrophages are slower to react as they 
age, and thus the inflammatory response to the pathological insult is delayed, 
resulting in delayed clearance of debris that inhibits remyelination [47].  
 Combined with these generic factors, each disease affecting 
oligodendrocytes may exert specific influence interfering with remyelination. In 
MS for example, an abnormality in expression of semaphorins appears to inhibit  
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proper migration of OPCs to the sites where they are needed [48]. Moreover, the 
disease process can affect OPCs directly, as specific antibodies directed against 
the OPC proteoglycan NG2 raise the possibility of an immune attack on this cell 
type [49]. 
 In the light of inadequate endogenous remyelination, two avenues of 
treatment are possible. One option is to address the failure of, and enhance the 
intrinsic mechanism. Proponents of this method argue that since complete 
remyelination is possible, there ought to be a way to identify its shortcomings 
when it fails, and address those with non-invasive methods. No meaningful 
progress has however been made in this area to date [13].    
 On the other hand, transplantation methods aimed at establishing 
remyelination have been studied extensively over the past three decades [50-52]. 
Transplantation of oligodendrocytes themselves did not yield any success likely 
due to the inability of such mature cells to myelinate [53]. A variety of other cell 
types, including OPCs [54-56], have all been able to restore myelin after 
transplantation into different models of demyelination. Such cells include 
Schwann cells, for which a clinical trial addressing spinal cord injury is under way 
[50, 57, 58], and olfactory ensheathing cells [59-61]. Neural stem cell lines [62], 
and embryonic stem cell derived glial precursors [63] have also shown new 
myelin formation, probably due to their differentiation into OPCs and eventually 
oligodendrocytes. These studies serve as proof of principle that the cell therapy 
approach may be feasible.  
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OPC transplantation and iPS cell derived OPCs 
 
 Significant leaps have been made in the field of cell based therapy aimed 
at remyelination. Embryonic stem cell derived glial precursors have been applied 
in phase I clinical trials for Pelizaeus-Merzbacher disease, and in spinal cord 
injury. Although the latter study was abandoned due to financial reasons, the 
former demonstrated a safe profile, at least during the first year following 
transplantation [64, 65].  
Despite such progress, many questions remain relating to both cell type 
and optimizing their delivery. Cell numbers are limited, as is their expansion 
potential, thus necessitating repeated harvesting of tissues that are very difficult 
to come by. Utilizing human embryonic stem cells to culture glial progenitor cells, 
and OPCs in particular, is an attractive method, however requires 
immunosuppression of the host, due to allogenicity [66].  
 The advent of induced pluripotent stem cell technology is promising in 
several regards. iPS cells are generated by forced expression of several 
transcription factors which lead to reprogramming of the cell’s genome activity 
and revert it to a state of pluripotency. Such reprogrammed cells are defined by 
their ability to form all three germ layers, teratomas, infinite division under defined 
culture conditions, and expression of markers of pluripotency [67]. This approach 
enables us to generate pluripotent cells from adult somatic sources, thus 
eliminating any concern for limited supply. Also, it is possible to generate stem  
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cells on an individual basis, circumventing the issue of immune rejection, should 
they be applied in transplantation therapies.  
OPCs have already been derived from mouse iPS cells but the published 
protocols have very low yields [68, 69].  Although OPCs can be generated from 
human iPS cells [70], the mouse cell remains a valuable model in which to further 
the understanding of mechanisms of their differentiation. The generation of iPS 
cells currently requires genome manipulation. The risk of insertional mutagenesis 
that is inherent to retroviral approaches currently prevents these cells from being 
eligible for clinical trials. As better methods are rapidly developed, such as non-
integrating viral vectors, and non-viral methods of genome editing, the iPS cell 
could reach clinical potential. Further human trials may be underway sooner than 
anticipated, but the ability to analyze tissue post-transplant remains a great 
advantage of animal studies. Such studies may enable us to gain further insights 
into remyelination, and possibly open doors to further improvement and 
enhancement of the process. Published protocols designed to direct 
differentiation of mouse derived stem cells into OPCs share several aspects, but 
diverge mostly in timing, as outlined in Table 1. A discrepancy in yields is 
observed between protocols designed for mouse iPS cells and those for 
embryonic stem cells.  With that in mind, we sought to improve upon the existing 
protocols attempting to differentiate OPCs from iPS cells.  
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Table 1. Summary of published protocols for directed differentiation of stem cells into 
OPCs and oligodendrocytes: Tokumoto et al. [69], Czepiel et al. [68], Jiang et al. [72], 
Najm et al. [73]. ES: embryonic stem cell; EpiSC: Epiblast stem cell; EB: embryoid 
body; ES medium: embryonic stem cell medium with serum; KSR: Knockout serum 
replacement medium; N2: N2 supplemented neurobasal medium; PolyO: poly-L-
ornithine coating; RA: Retinoic acid; PUR: purmorphamine; NOGG:  noggin; DORS: 
dorsomorphin; SHH: sonic hedgehog.   
MATERIALS AND METHODS 
 
General Experiment Outline 
 
Due to the high yields achieved with mouse embryonic stem cells, and the 
characteristics they share with iPS cells, we initially set out to apply the protocol 
devised for ES cell differentiation into OPCs [72] on mouse iPS cells. After failing 
to achieve comparable results, the latter, OPC expansion part of the protocol 
devised by Nejm et al. [73] was added, leading to much improved results as 
described below.  
 
iPS Cell Reprogramming and culture 
 
Mouse iPS cell lines were generated and characterized as described 
previously[71]. Three cell lines expressing green fluorescent protein were 
subjected to the main experiments: 3F10, JG2, and JBl6. The 3F10 line harbors 
tamoxifen-inducible Cre recombinase MerCreMer, under the control of the 
endogenous Oct4 locus, as well as the double fluorescent mT/mG Cre reporter. 
This construct allows us to replace expression of tdTomato with enhanced green 
fluorescence protein (eGFP) via exposure to tamoxifen [71]. iPS cells were 
cultured on irradiated embryonic mouse fibroblasts in mES media (Knockout- 
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DMEM (Gibco) containing: 20% fetal bovine serum (HyClone), 1X NEAA, 1X L-
Glutamine, 100µM 2-mercaptoethanol (Sigma) supplemented with LIF (1000u/ml 
Millipore) at 37oC in 5% CO2.  
 
OPC differentiation protocol 
 
Day Zero: The iPS cells and feeder cells were disaggregated from plates using 
TrypLE Express (Gibco). They were subsequently transferred into the KnockOut 
Serum Embryoid Body media: MEM/EBSS (HyClone), supplemented with 20% 
KnockOut SR (Gibco), 1mM sodium pyruvate (Sigma), 1 % MEM non- essential 
amino acids (Gibco), 0.1 mM 2-Mercaptoethanol (Sigma), and 1 % Anti-Anti 
(Gibco).  
The cells were left in suspension in Ultra-Low Attachment Surface 6 well plates 
(Costar), at a density of 500,000 cells per well, where they were left to aggregate 
into embryoid bodies. They were kept in the KnockOut Serum Embryoid Body 
media for 3 days, with daily change of media starting on day two.  
On day 4, the media was supplemented with 0.2 micromolar Retinoic Acid 
(Sigma), and on day five, Retinoic acid and 1 micromolar Purmorphamine 
(Cayman Chemical).  
On day six, the embryoid bodies were switched to the N-2 supplemented media: 
MEM/EBSS (HyClone), supplemented with N-2 Supplement (Gibco), 1mM 
 sodium pyruvate (Sigma), 1 % MEM non- essential amino acids (Gibco), 0.1 mM  
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2-Mercaptoethanol (Sigma), and 1 % Anti-Anti (Gibco). That media was changed 
daily until day 8.  
On day 8, the embryoid bodies were treated with TrypLE Express (Gibco), and 
transferred into the OPC selecting media: DMEM / F12 (Gibco), supplemented 
with 1x B-27 Supplement (Gibco), 1x N-2 MAX Media Supplement (R&D 
Systems), 20 ng/mL of FGF-2, 20 ng/mL of rhPDGF-AA, 200 ng/mL of rhShh 
(R&D Systems), and 1 % Anti-Anti (Gibco). 
The embryoid bodies were plated onto tissue culture plates coated with Poly-L-
ornithine (Sigma), and the media was changed every other day. They were left to 
grow to confluence, and passaged in a 1:2 ratio.  
 
Immunocytochemical Characterization 
 
Cultured cells were fixed using 10% formalin for 10 minutes and then washed 
three times with PBS. Where necessary, cells were permeabilized using 1% 
Tween in PBS for 5 minutes. The cells were incubated with blocking buffer (1%  
bovine serum albumin (BSA) in PBS with 0.1%Tween 20) for 30 minutes. Cells 
were incubated overnight at 4°C with primary antibodies diluted in blocking 
buffer. After washing three times in PBS-T the cells were incubated with 
secondary antibodies diluted in blocking buffer for 2 hours at room temperature 
before final washing. For the primary antibody directed against NG2, the 
permeabilization step was substituted by antigen retrieval (5 minutes in L.A.B.  
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Solution, 24310, Polysciences Inc.), and all detergent was omitted from the 
blocking and washing solutions.  
 
Primary antibodies: glial fibrillary acidic protein (MAB360, 1/400, Millipore), β-
tubulin III (T8660, 1/400, Sigma-Aldrich), MBP (AB7349, Abcam), A2B5 
(MAB312, 1/250, Millipore), Olig2 (AB9610, 1/250, Millipore), PDGFRα (sc-338, 
1/400, Santa Cruz Biotechnology), Olig 1 (MAB5540, 1/100, Millipore), Nestin 
(NES, Aves Labs), and NG2 (AB5320, 1/100, Millipore).  
Secondary antibodies:  Alexa Fluor 555 F(ab')2 fragment of goat anti-mouse IgG 
(H+L) (Invitrogen A21425), Alexa Fluor 555 donkey anti-rabbit IgG (H+L) 
(Invitrogen A31572), Alexa Fluor 555 goat anti-mouse IgM (µ chain) (Invitrogen 
A21426), and Alexa Fluor 633 goat anti-mouse IgM (µ chain). 
Nuclear contrast was performed with Hoechst nuclear stain (Thermo Scientific). 
 
Fluorescence Microscopy 
 
Direct fluorescence imaging of live cells, fixed cells and fixed and sectioned 
tissues was performed using DMI 6000B inverted microscope (Leica) equipped 
with an automated stage and cell culture chamber. Images were captured using 
a Retiga 2000R camera (QImaging) using IP Lab software (BD Biosciences). 
EGFP and dTomato expression was detected directly in live and fixed cells.  
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Total RNA extraction and analysis 
 
Total RNA was prepared from EBs and cells using the RNeasy MiniKit (Qiagen). 
Genomic DNA was removed from RNA by DNase (Promega) treatment for 1h at 
37C. cDNA was generated by reverse transcription from 2 μg total RNA using 
SuperScript III Reverse Transcriptase and oligo(dT)20 primers (Invitrogen). 
Quantitative gene expression was analyzed in an Eppendorf lightcycler using 
predesigned primers (IDT) for the following genes: APC, CNP, GAPDH, GFAP, 
MBP, Nanog, Nestin, Oct4, Pax 6, Olig1, Olig2, PDGFRa, Nkx 2.2, Syn1, Tuj 1. 
Samples from three biological replicates were analyzed and results are indicated 
as means in bar graphs on a logarithmic scale, with standard error bars.  
 
Cell Transplantation 
 
Shiverer mice were obtained from the Jackson Laboratories. Mice were 
anesthetized with ketamine-xylazine and a burr hole was used as the access for 
stereotactic injection of cells. Injection coordinates were measured from the 
bregma: 0.4 mm anterior, 2.2 mm lateral, and at depths of 2.5 and 3.0 mm. Cells 
were injected at 25,000 per microliter, with a total of 10 microliters. The animals 
were maintained until 4 and 6 weeks post injection, at which point they were 
sacrificed, and their brains processed for immunohistochemical analysis and 
electron microscopy. 
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Immunohistochemical analysis of transplanted cells 
 
After sacrifice, mice were perfused transcardially with 4% formaldehyde. The 
brains were removed and stored in 30% sucrose at 4°C until they were 
embedded in O.C.T. (Tissue-Tek), and frozen. 7-9 M sections were    
Leica CM 3050S cryostat. Transplanted cells were identified by eGFP expression 
under fluorescence microscopy. Primary antibodies: glial fibrillary acidic protein 
(MAB360, 1/400, Millipore), β-tubulin III (T8660, 1/400, Sigma-Aldrich), and MBP.  
 
RESULTS 
 
Generation of OPCs 
 
The initial attempt of applying the protocol devised by Jiang et al. [72] did not 
yield successful results. The embryoid bodies failed to attach following the initial 
eight days of the protocol, and ultimately cells failed to expand. Only after all the 
factors inducing OPC proliferation were combined [73], did we see survival and 
expansion of the OPC population beyond eight days.  
Our protocol for generating OPCs from mouse iPS cells is outlined in Figure 2. 
Mouse iPS cells are initially left in KSR media to aggregate into embryoid bodies 
in ultra-low attachments plates. Subsequently, the media is changed daily, with 
addition of retinoic acid on the fourth, and purmorphamine on the fifth day. On 
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the sixth day, KSR media is substituted by N2 supplemented media, retaining 
retinoic acid and purmorphamine. On day 8, the embryoid bodies are treated with 
trypleE, and plated on poly-L-ornithine coated tissue culture plates, where they 
expand in OPC media containing PDGF-AA, sonic hedgehog, and FGF.  
Three cell lines were subjected to the protocol: 3F10, JBl6, and JG2. 3F10 and 
JBl6 were from transgenic animals expressing eGFP.  
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 Figure 2. Modified differentiation protocol for generating OPCs from pluripotent mouse iPS cells. 
The protocol is divided into three stages: iPS cell maintenance, neuroglial patterning, and OPC 
expansion. The conditions in each stage are summarized in the right column of the table. 
Representative micrographs are shown, in phase contrast and green fluorescence imaging, in the 
middle column. 
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Characterization of OPCs 
 
Quantitative RT PCR was used to assess expression of key marker genes at 
various stages of the OPC differentiation protocol (Figure 3). Gene expression 
was compared to controls of wild type animals at embryonic day 14, lacking 
mature oligodendrocytes, and those old three weeks, when myelination is 
actively happening. A continuous decrease was seen in the expression of Oct 4 
and Nanog, genes of pluripotency, while genes associated with neuroglial 
precursors are gradually upregulated (Figure 3A). Upregulation of genes 
associated with the OPC identity, such as Olig 2, Olig1, and PDGFRα, is noted 
starting on day 8 (Figure 3B). Genes ordinarily expressed in mature 
oligodendrocytes, are found at minimal levels throughout the protocol, as are 
those characteristic of neurons (Figure 3C).   
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 Figure 3. Quantitative analysis of gene expression during differentiation of mouse iPS cells into 
OPCs. Gene expression on specific days of the differentiation protocol is shown for specific 
genes. Gene expression is normalized to GAPDH and expressed relative to GAPDH expression. 
E14 and 3wk represent gene expression in brain tissue from embryonic day 14 and 21 days post 
natal mice. 
 
Immunocytochemistry confirmed the presence of a variety of OPC markers 
including Olig 2, Olig 1, PDGFRα, NG 2, A2B5, and Nestin. Markers of the 
neuronal and astrocytic lineages were also seen, albeit with very low frequency 
(Figure 4). Markers characteristic of mature oligodendrocytes were not observed, 
along with markers of pluripotency. We used immunocytochemistry to quantify 
24 
 Figure 4. Immunocytochemical analysis of d25 OPCs. Immunocytochemistry demonstrating 
presence and co-labeling of OPC markers Olig 2, A2B5, as well as Olig 1, NG 2, PDGFRα, and 
nestin. Occasional presence of neuronal (Beta III), and astrocytic (GFAP) markers was observed. 
All scale bars represent 50 μm.  
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OPCs and other cell types in culture following 25 days of the protocol (Figure 5). 
Two of the three cell lines that were subjected to the protocol yielded 88 and 82 
% of Olig 2 positive cells, and both had greater than 70 % double positivity for 
Olig 2 and A2B5. The third cell line, JG2, demonstrated a more modest yield of 
47 % Olig 2 expressing cells (Table 2).  
 
 
Figure 5. Expression of OPC, neural, and glial markers following 25 days of OPC differentiation 
protocol. Cultures were immunostained for Olig 2, A2B5, PDGFRα, NG 2, GFAP, and beta III 
tubulin. The proportion of immunopositive cells was scored for each marker and each cell line: 
3F10, JBl6, and JG2. At least three repeats were performed in each group. Data are provided as 
means  ± SEM. 
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 In vivo myelination 
 
In order to assess functionality of OPCs generated via our protocol in vivo, they 
were transplanted into brains of shiverer mice – a model of congenital 
dysmyelination, lacking mature oligodendrocytes and myelin basic protein. The 
mice were maintained for four weeks following transplantation and their brains 
were subsequently obtained for immunohistochemical analysis. The transplanted 
OPCs demonstrate ability to migrate, as eGFP positive cells appear in a 
circumferential distribution surrounding the initial site of transplantation (Figure 6. 
A, D). Furthermore, myelin basic protein is observed, indicating presence of  
mature oligodendrocytes (Figure 6. B, C).  
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Table 2. Expression of OPC, neural, and glial markers 
following 25 days of OPC differentiation protocol. 
Percentage of cells scoring positive for detection of 
respective antigen by immunocytochemistry. 
Percentages illustrated in Figure 5.  
 Figure 6.  Functional analysis of OPCs following transplantation into Shiverer mouse brains. A, B. 
Differentiating OPCs 28 days following transplantation, eGFP and Neurofilament (red). C, D. 
Myelin expression by OPCs 28 days after transplantation, eGFP and MBP (red). Scale bars (A) 
500 μm, 200 μm (B), 50 μm (C), 100 μm (D). 
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Discussion 
 
In the present study, we demonstrate a novel protocol for derivation of 
OPCs from mouse iPS cells. Although two methods have been previously 
described, they report rather low efficiencies, with OPC and oligodendrocyte 
yields ranging from 12 to 18%[68, 69]. In contrast, our yield exceeds 80%.  
Our protocol was devised through optimization and combination of elements from 
existing protocols intended for OPC derivation from mouse embryonic and 
epiblast stem cells [72, 73].  
We initially set out to replicate the protocol devised by Jiang et al. with the 
hypothesis that similarities between embryonic stem cells would lead to parallel 
results.  Following the initial eight days however, the cells failed to attach in 
culture and proliferate. After the addition of OPC media, as outlined by Najm et 
al., containing Shh, PDGF-AA, and FGF, cell survival, attachment, and 
proliferation improved significantly. 
 
The protocol consists of several transitions through defined media, aimed 
to replicate the developmental environment favoring differentiation of OPCs.  
Stage two of the protocol was adopted from Deng et al. [72], guiding the initial 
cohort of iPS cells to a neuroglial fate over a period of 8 days. Retinoic acid, 
added on day 4, supports neural specification whilst inhibiting mesodermal 
differentiation via blockade of the Nodal signaling pathway[74]. Subsequently, the 
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SHH pathway is activated by addition of purmorphamine (reference), and directs  
neural progenitors toward the OPC fate by upregulating genes essential for OPC 
specification, such as Sox 10, Olig 2, and Nkx 2.2 [75-77].  
The third stage utilizes PDGF-AA, a factor known to promote proliferation and 
differentiation of pre-OPC progenitors into OPCs. FGF is a potent mitogen that 
aids expansion of OPCs, along with the support of SHH which potentiates the 
drive toward the OPC fate. Thus, during this stage, the cell population is enriched 
with OPCs through targeted proliferation of this cell type [78].  
 
Characterization of OPCs was accomplished utilizing a panel of 
established OPC markers via immunocytochemistry, as well as RT-PCR.  
Immunostaining revealed presence of all the OPC markers in comparable 
amounts, with the exception of NG 2. Lower detection of this surface 
proteoglycan molecule may be explained by technical difficulty of its preservation 
through the fixation and staining process, as has been described previously in 
literature[39]. It certainly proved to be a challenging task to optimize the 
immunostaining protocol for this particular marker.  
On the other hand, the sequence and timing of expression and co-expression of 
OPC markers still remains to be defined. The differentiation pathway of an OPC 
toward a mature oligodendrocyte, although a continuous spectrum, may harbor a 
variety of pre-OPC subtypes [78]. Thus, it is possible that NG 2 may not be highly 
expressed during all stages of the OPC lifetime.  
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RT-PCR revealed an increase in expression of genes characteristic for OPCs, 
such as Olig 1 and 2, Nkx 2.2, and PDGFRα. This not only corroborates our 
immunocytochemical findings, but also reveals a temporal profile of gene activity 
during the various stages of the protocol. While there is a gradual increase in 
expression of OPC defining genes, there is a decline in expression of genes 
related to  pluripotency, such as Oct 4 and Nanog. An expected increase in 
expression of Nestin and Pax 6, characteristic of neuroepithelial precursors, is 
seen as well. Markers of mature oligodendrocytes, MBP, APC, and CNP, do not 
demonstrate a significant expression. Markers of neurons and astrocytes 
however are expressed in trace amounts, as observed by the presence of those 
cell types in culture.  
 
In contrast to the previously reported studies, we used three different iPS 
cell lines to demonstrate efficiency and robustness of our protocol.  While 
comparable results were achieved with two of the cell lines, 3F10 and JBl6, the 
yield from JG2 was a modest 47%, as judged by Olig 2 expression. 
Nevertheless, the number is significantly greater in comparison to previous 
reports in literature. This discrepancy however may be due to several reasons, 
the major concern of which would be underlying difference between iPS cell lines 
that lies beyond the reach of our standard characterization methods. Further 
research into the nature of iPS cells and epigenetic phenomena of cell 
reprogramming may shed more light on this subject.  
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The ultimate confirmation of OPC functionality comes from in vivo 
transplantation studies. Of the two previously published protocols for 
differentiation of mouse iPS cells to OPCs, only one demonstrated such 
evidence[68]. The shiverer mouse carries an autosomal recessive mutation (shi) 
that results in lack of myelin and MBP expression. As such, it is an excellent 
model of congenital dysmyelination. By transplanting OPCs into brains of 
shiverer mice it is possible to assess the capability of OPCs to differentiate into 
mature oligodendrocytes. Such oligodendrocytes will give rise to MBP that is 
undetectable in control animals. OPCs generated with our protocol were indeed 
able to give rise to MBP, and thus we can infer mature oligodendrocytes. The 
fact that the transplanted cells express eGFP facilitated their observation under 
fluorescence microscopy. Furthermore, co-localization of MBP and eGFP signals 
provides evidence that the formed myelin stems from the transplanted cell 
population.  
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